H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

6 years ago
Deals

AI-fo­cused No­table Labs score $40M in fund­ing; Seat­tle Ge­net­ics/Astel­las sub­mit mar­ket­ing ap­pli­ca­tion for en­for­tum­ab ...

6 years ago
News Briefing

Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

6 years ago
Deals

As ri­vals march on, No­var­tis se­cures pri­or­i­ty FDA re­view for sick­le cell dis­ease ther­a­py

6 years ago
R&D
FDA+

Keen to stay out front in cell ther­a­py, Gilead­'s Kite builds its own vi­ral vec­tor man­u­fac­tur­ing op­er­a­tions

6 years ago
Cell/Gene Tx

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al ...

6 years ago
People
Financing

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

6 years ago
Deals
Discovery

San Diego oph­thalmic biotech up­start rais­es $28M on al­ter­na­tive to corneal trans­plant

6 years ago
Financing
Startups

Deal hun­gry So­sei Hep­tares brings Roche's Genen­tech on board as a part­ner

6 years ago
Deals

AM-Phar­ma gath­ers €116M for PhI­II pro­gram on kid­ney drug Pfiz­er passed on

6 years ago
Financing

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

6 years ago
People
Cell/Gene Tx

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

6 years ago
R&D
Cell/Gene Tx

Alk­er­mes adds bipo­lar I dis­or­der to its FDA wish­list; Con­go con­firms first Ebo­la case in large city

6 years ago
News Briefing

Pe­ter Kolchin­sky and Raj Shah raise a $300M fund de­vot­ed to biotech star­tups

6 years ago
Financing
Startups

Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

6 years ago
Deals

Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

6 years ago
Deals

Billing it­self as the first AI biotech to launch hu­man tri­als, Re­cur­sion adds $121M C round

6 years ago
Financing

Eton Phar­ma hand­ed CRL for re­for­mu­lat­ed con­junc­tivi­tis eye drop

6 years ago
R&D
FDA+

FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

6 years ago
R&D

GSK to tap Jonathan Symonds as chair­man, lever­ag­ing Big Phar­ma ex­pe­ri­ence for con­sumer biz deal

6 years ago
People

Hal Bar­ron's team at GSK scores a win with pos­i­tive Ze­ju­la PhI­II front­line study — now comes the hard part

6 years ago
R&D

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
Deals
R&D

Sofinno­va lends Abi­Vax a hand for PhII an­ti-in­flam­ma­to­ry tri­als, pick­ing up €12M worth of stock

6 years ago
Financing

Reckitt Benckiser shells $1.4B to set­tle US probe; NICE backs di­a­betes, pso­ri­a­sis treat­ments

6 years ago
News Briefing
First page Previous page 918919920921922923924 Next page Last page
A service from the Financial Times